Morphic Holding, Inc (MORF)

Etorro trading 970x250
Morphic Holding, Inc (MORF) Logo

About Morphic Holding, Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß1 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children’s Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts. Address: 35 Gatehouse Drive, A2, Waltham, MA, United States, 02451

Morphic Holding, Inc News and around…

Latest news about Morphic Holding, Inc (MORF) common stock and company :

Morphic Announces Participation in Upcoming Investor Conferences
16 Nov, 2021 Yahoo! Finance

WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation in the upcoming investor conferences: Dr. Bruce N. Rogers will give a company update at the Jefferies London Healthcare Conference at 1:40 PM GMT on Wednesday, November 17thMembers of the Morphic management team will provide a Company update at the 4th A

Morphic Holding Breaks Below 200-Day Moving Average - Notable for MORF
15 Nov, 2021 FinancialContent

In trading on Monday, shares of Morphic Holding Inc (MORF) crossed below their 200 day moving average of $56.87, changing hands as low as $54.87 per share. Morphic Holding Inc shares are currently trading off about 11.8% on the day..

Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
15 Nov, 2021 Yahoo! Finance

αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination immunotherapy to drive anti-tumor response via TGFβ pathway WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the presentation o

Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates
04 Nov, 2021 Yahoo! Finance

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 9.21% and -47.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results
04 Nov, 2021 Yahoo! Finance

MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22 Announced appointment of Nisha Nanda, Ph.D., to Morphic Board of Directors WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results

CFO And COO Of Morphic Holding Trades $510K In Company Stock
04 Nov, 2021 Yahoo! Finance

Marc Schegerin, CFO And COO at Morphic Holding (NASDAQ:MORF), made a large buy and sell of company shares on November 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Marc Schegerin exercised options to purchase 5,477 Morphic Holding shares at a price of $15.00 per share for a total of $82,155 on November 2. They then sold their shares on succeeding transactions in the open market. They sold at prices ranging from $15.0

Analysts Estimate Morphic Holding, Inc. (MORF) to Report a Decline in Earnings: What to Look Out for
01 Nov, 2021 Yahoo! Finance

Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Hedge Funds Love Morphic Holding, Inc. (MORF)?
29 Oct, 2021 Yahoo! Finance

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 873 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of June 30th, 2021. […]

Sum Up The Parts: FYX Could Be Worth $108
26 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Core AlphaDEX Fund ETF (FYX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $107.79 per unit.

Investing in Morphic Holding (NASDAQ:MORF) a year ago would have delivered you a 103% gain
25 Oct, 2021 Yahoo! Finance

Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...

CFO And COO Of Morphic Holding Trades $2.2M In Company Stock
18 Oct, 2021 FinancialContent

Marc Schegerin, CFO And COO at Morphic Holding (NASDAQ:MORF), made a large buy and sell of company shares on October 15, according to ...

Morphic to Participate in Jefferies IBD Therapeutics Summit
12 Oct, 2021 Yahoo! Finance

WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to take part in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021 at 3:15 p.m. ET. A live webcast of the Jefferies fireside chat will be available on the Investor

MORF Crosses Below Key Moving Average Level
04 Oct, 2021 FinancialContent

In trading on Monday, shares of Morphic Holding Inc (MORF) crossed below their 200 day moving average of $52.80, changing hands as low as $52.12 per share. Morphic Holding Inc shares are currently trading off about 2% on the day..

How The Pieces Add Up: PTH Targets $199
23 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $198.92 per unit.

Insider Of Morphic Holding Trades $861.86 Thousand In Company Stock
15 Sep, 2021 Yahoo! Finance

Robert Farrell Jr., insider at Morphic Holding (NASDAQ:MORF), made a large buy and sell of company shares on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Robert Farrell Jr. purchased 4,974 Morphic Holding shares at a price of $4.32 per share for a total of $21,488 on September 13. They then sold their shares on multiple transactions in the open market. They sold at prices ranging from $65.01 to $65.14 to

Top Buys by Directors: Springer's $31.4M Bet on MORF
08 Sep, 2021 FinancialContent

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Morphic Therapeutic Announces Participation in September Investor Conferences
01 Sep, 2021 FinancialContent
Insider Buying: The Morphic Holding, Inc. (NASDAQ:MORF) Founder Just Bought 1.4% More Shares
24 Aug, 2021 Yahoo! Finance

Those following along with Morphic Holding, Inc. ( NASDAQ:MORF ) will no doubt be intrigued by the recent purchase of...

Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
23 Aug, 2021 FinancialContent
The Past Week's Notable Insider Buys Include AppLovin, Cricut, Biotechs, And More
21 Aug, 2021 FinancialContent

With earnings-reporting season all but over, many insiders are free once more to buy or sell shares. Here are a few of the most noteworthy insider purchases that were reported in the past week.

The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More
21 Aug, 2021 FinancialContent

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some ...

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Misses Revenue Estimates
04 Aug, 2021 Yahoo! Finance

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -40.00% and -35.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results
04 Aug, 2021 FinancialContent
Earnings Preview: Morphic Holding, Inc. (MORF) Q2 Earnings Expected to Decline
02 Aug, 2021 Yahoo! Finance

Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hedge Funds Are Crazy About Morphic Holding, Inc. (MORF)
19 Jul, 2021 Yahoo! Finance

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

How The Parts Add Up: TUSA Targets $52
14 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Total US Market AlphaDEX ETF (TUSA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $52.50 per unit.

Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
09 Jul, 2021 FinancialContent

Morphic Therapeutic(NASDAQ: MORF)has announced additional datafrom its Phase 1 trial evaluating MORF-057 for ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
09 Jul, 2021 FinancialContent
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
08 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Morphic Holding, Inc (MORF) is a NASDAQ Common Stock listed in , ,

970x250